Author:
Long Brian R.,Sandza Krystal,Holcomb Jennifer,Crockett Lucy,Hayes Gregory M.,Arens Jeremy,Fonck Carlos,Tsuruda Laurie S.,Schweighardt Becky,O’Neill Charles A.,Zoog Stephen,Vettermann Christian
Funder
BioMarin Pharmaceutical Inc
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference41 articles.
1. Adeno-associated virus vectors for gene therapy;Flotte;Gene Ther.,1995
2. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins;Nathwani;Mol. Ther.,2011
3. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response;Manno;Nat. Med.,2006
4. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors;Boutin;Hum. Gene Ther.,2010
5. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses;Calcedo;J. Infect. Dis.,2009
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献